London, United Kingdom

Michelle Leanne Styles


Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 67(Granted Patents)


Location History:

  • Golden Square, AU (2009)
  • London, GB (2012)

Company Filing History:


Years Active: 2009-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michelle Leanne Styles: Innovator in Kinase Inhibitors

Introduction

Michelle Leanne Styles is a prominent inventor based in London, GB. She has made significant contributions to the field of biochemistry, particularly in the development of selective kinase inhibitors. With a total of two patents to her name, her work has the potential to impact the treatment of various diseases.

Latest Patents

One of her latest patents is titled "Benzimidazoles as selective kinase inhibitors." This invention involves a compound of a general formula that includes various nitrogen-containing heterocyclic rings and methods for treating tyrosine kinase-associated diseases. The patent also discusses compositions that comprise a carrier and at least one compound of the specified formula. Another notable patent is "Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof." This invention focuses on X-ray crystallography studies of the JAK2 domain and its potential applications in selecting compounds for treating diseases related to JAK2 activity.

Career Highlights

Michelle has worked with notable companies such as Cytopia Research Pty Ltd and Ym Biosciences Australia Pty Ltd. Her experience in these organizations has contributed to her expertise in the field of kinase inhibitors and drug development.

Collaborations

Some of her coworkers include Andrew Frederick Wilks and Christopher John Burns. Their collaboration has likely enhanced the research and development efforts in their respective projects.

Conclusion

Michelle Leanne Styles is a distinguished inventor whose work in kinase inhibitors and related fields showcases her innovative spirit and dedication to advancing medical science. Her contributions are paving the way for new treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…